Robert F. Kennedy Jr.'s agenda to expand access to peptide drugs is a dangerous gamble that could exacerbate health inequities and open the door to exploitation by unscrupulous actors. By dismantling public health safeguards in favor of individual choice, Kennedy is effectively abandoning the most vulnerable members of society.

The 'Make America Healthy Again' (Maha) agenda, championed by Secretary Kennedy, presents a facade of freedom while dismantling crucial protections. The proposal to make 14 injectable peptide drugs available to the public, despite the FDA's previous safety concerns, exemplifies this reckless approach. These peptides, many of which lack proven safety or efficacy, are being pushed into the market without adequate oversight.

Peptides, molecules used by the body for signaling, have varying functions. While some show promise, others, like the toxic compounds in snake venom, are dangerous. The FDA restricted 17 peptides in 2023 due to 'potential significant safety risks,' a decision Kennedy is now effectively reversing, without new scientific evidence to justify the change.

This initiative aligns with Kennedy's broader philosophy of deregulation, which prioritizes individual autonomy over collective well-being. By dismantling regulations, Maha creates an environment where corporations can profit at the expense of public health. This approach disproportionately harms marginalized communities, who often lack the resources to navigate complex health information and are more vulnerable to misinformation.

The idea that individuals can simply 'do their own research' ignores the realities of health literacy and access to reliable information. Many people lack the scientific background to evaluate complex medical claims, making them susceptible to deceptive marketing and false promises. This is especially true for low-income communities and communities of color, who face systemic barriers to accessing quality healthcare and accurate information.

The burgeoning market for peptides, particularly for 'biological enhancement,' is driven by a culture of optimization and self-improvement, primarily among affluent tech workers in Silicon Valley. This trend highlights the widening gap between the haves and have-nots, where the wealthy can afford to experiment with unproven treatments while others struggle to access basic healthcare.